Radiological evaluation of a Chondromyxoid Fibroma
Journal Title: Journal of Radiology and Oncology - Year 2017, Vol 1, Issue 2
Abstract
Chondromyxoid fibroma (CMF) is a very rare benign cartilaginous tumor representing less than 0.5% of all bone tumors while also being the rarest cartilaginous bone tumor. Common locations of occurrence include the metaphysial region of the proximal tibia and distal femur. We report a case of a 10-year-old female affected by a CMF of the left lower tibia. The radiological features demonstrated by X-ray and magnetic resonance imaging (MRI) are discussed.
Authors and Affiliations
A Fletcher, M Mastragostino
Keywords
Related Articles
- EP ID EP541134
- DOI 10.29328/journal.jro.1001008
- Views 102
- Downloads 0
A Short Synthesis Concerning Biological Effects and Equivalent Doses in Radiotherapy
The limits of classical equivalent computation based on time, dose, and fractionation (TDF) and linear quadratic models have been known for a long time. Medical physicists and physicians are required to provide fast and...
Time to Terminate LNT: Radiation Regulators Should Adopt LT
The linear no-threshold hypothesis (LNT)-the basis of radiation regulatory policy-extrapolates from observed high-dose harm to assumed low-dose harm, entailing that all ionizing radiation is harmful, by denying any biolo...
Inter-Observer Variability of a Commercial Patient Positioning and Verification System in Proton Therapy
Purpose:Accurate patient positioning is crucial in radiation therapy. To fully benefit from the preciseness of proton therapy, image guided patient positioning and verification system is typically utilized in proton ther...
Synthesis, Radioiodination and Biological distribution of 5-(5-(tributylstannyl) benzofuran-2-yl) pyridin-2-amine as an amyloid imaging agent
In this work an efficient method developed for the synthesis of 125I-benzofuran-2-yl) pyridin-2-amine (125IBPA), followed by radioiodination with 125I by using Chloramine-T at pH 8. The reaction proceeds within 10 min at...
Ra-223 dichloride management in a Nuclear Medicine Unit: experience of a referral institution
Ra-223 dichloride is a first-in-class alpha-emitting radiopharmaceutical recently introduced into clinical practice for treatment of men with Castration-Resistant Prostate Cancer (CRPC) and symptomatic bone metastases. D...